{ "ok": true, "cik": "1337013", "ticker": "INFU", "name": "INFUSYSTEM HOLDINGS, INC", "filings": [ { "form": "8-K", "filed": "2026-09-17", "items": [ "7.01 Regulation FD Disclosure" ], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026062520/0001628280-26-062520-index.htm" }, { "form": "10-Q", "filed": "2026-08-04", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026052462/0001628280-26-052462-index.htm" }, { "form": "8-K", "filed": "2026-08-04", "items": [ "7.01 Regulation FD Disclosure" ], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026052123/0001628280-26-052123-index.htm" }, { "form": "8-K", "filed": "2026-08-04", "items": [ "2.02 Results of Operations and Financial Condition" ], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026052112/0001628280-26-052112-index.htm" }, { "form": "8-K", "filed": "2026-07-28", "items": [ "7.01 Regulation FD Disclosure" ], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026049931/0001628280-26-049931-index.htm" }, { "form": "8-K", "filed": "2026-05-18", "items": [ "7.01 Regulation FD Disclosure" ], "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026035967/0001628280-26-035967-index.htm" } ], "events12m": 21, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001337013.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1337013" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up INFUSYSTEM HOLDINGS, INC ($INFU). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-17. 21 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-03-19.", "auditor": { "changes": [ { "filed": "2026-03-19", "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026019649/0001628280-26-019649-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 143436000, "revenueGrowth1y": 0.06358398647496322, "revenueGrowthPerYear": 0.08794925497160433, "yearsOfData": 5, "operatingMargin": 0.08310326556791879, "operatingMarginPrior": 0.05109705548676044, "netMargin": 0.04620179034551995, "operatingCashFlow": 24408000, "capitalSpending": 560000, "freeCashFlow": 23848000, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 3186000, "longTermDebt": 19625000, "longTermDebtChange": -0.17763157894736847, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 102382000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 109914000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 125785000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 134861000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 143436000 } ], "totalEquity": 57326000, "totalAssets": 100560000, "equityRatio": 0.5700676213206046, "returnOnEquity": 0.11560199560408889, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 121988337.8730928, "high": 196065941.62716413, "baseline": 154650529.7579777, "n": 4309, "band": "b01" }, "ifPaceHeld": { "low": 121988337.8730928, "high": 196065941.62716413 } }, "edgarette": "🔖 Exposure: revenue $143.4M (FY2025), total debt $19.6M. Experience: revenue up 6.4% on the year, up 8.8% a year over 4 years; operating margin 8.3%, up from 5.1%. Soundness: equity 57.0% of assets, return on equity 11.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $122.0M and $196.1M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 8.3% against a 1.2% median; growth 6.4% against 11.6%.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "Infusystem Holdings (INFU) grew revenue 6.4% in FY2025 to $143 million, operating margin 8.3% against a 1.2% median for surgical & medical instruments & apparatus, equity 57.0% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
INFUSYSTEM HOLDINGS, INC against its own record and its peers
Operating marginPeer median 1.2%8.3%Revenue, on the yearPeer median 11.6%6.4%Equity of assetsPeer median 52.9%57.0%Return on equityPeer median -2.3%11.6%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 13, "hits": 13, "rate": 1, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:31.610Z", "hash": "6c4cd9e34cd5cdd6", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Infusystem Holdings (INFU) grew revenue 6.4% in FY2025 to $143 million, operating margin 8.3% against a 1.2% median for surgical & medical instruments & apparatus, equity 57.0% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 143436000, "totalDebt": 19625000, "cash": 3186000 }, "experience": { "revenueGrowth1y": 0.06358398647496322, "revenueGrowthPerYear": 0.08794925497160433, "operatingMargin": 0.08310326556791879, "operatingMarginPrior": 0.05109705548676044, "netMargin": 0.04620179034551995, "freeCashFlow": 23848000 }, "soundness": { "equityRatio": 0.5700676213206046, "returnOnEquity": 0.11560199560408889, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2026-03-19", "url": "https://www.sec.gov/Archives/edgar/data/1337013/000162828026019649/0001628280-26-019649-index.htm" } }, "range": { "low": 121988337.8730928, "high": 196065941.62716413, "baseline": 154650529.7579777, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 4309, "sizeBand": "b01" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 13, "hits": 13, "rate": 1, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:31.610Z", "hash": "6c4cd9e34cd5cdd6", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001337013.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1337013" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }